Insider Selling: Insmed Incorporated (NASDAQ:INSM) COO Sells $126,299.25 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,925 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total value of $126,299.25. Following the sale, the chief operating officer now directly owns 136,675 shares in the company, valued at approximately $8,967,246.75. The trade was a 1.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, May 13th, Roger Adsett sold 7,482 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $507,354.42.

Insmed Trading Up 1.3%

NASDAQ INSM opened at $68.12 on Friday. The firm’s 50 day moving average price is $71.57 and its two-hundred day moving average price is $73.12. The stock has a market cap of $12.41 billion, a price-to-earnings ratio of -12.19 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period last year, the business earned ($1.06) EPS. Equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently modified their holdings of INSM. Cullen Frost Bankers Inc. boosted its stake in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares during the period. Elequin Capital LP acquired a new stake in shares of Insmed during the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC boosted its stake in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 248 shares during the period. Finally, Spire Wealth Management acquired a new stake in shares of Insmed in the 4th quarter valued at $47,000.

Analyst Ratings Changes

Several research analysts have issued reports on INSM shares. Truist Financial lifted their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Monday, May 12th. Jefferies Financial Group started coverage on shares of Insmed in a research report on Tuesday, May 13th. They issued a “buy” rating and a $105.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.